Infectious Diseases
Showing 141-149 of 149 Results
-
Taia T. Wang, MD, PhD, MSCI
Associate Professor of Medicine (Infectious Diseases) and of Microbiology and Immunology
Current Research and Scholarly InterestsLaboratory of Mechanisms in Human Immunity and Disease Pathogenesis
-
Eitan Yaffe
Affiliate, Medicine - Med/Infectious Diseases
BioDr. Eitan Yaffe is a computational biologist studying the evolution of natural microbial communities under selective pressures, such as antibiotics. He is currently a research associate in the lab of Dr. David Relman at Stanford University, where he develops experimental and computational approaches to investigate strain dynamics, horizontal gene transfer, and the emergence of antimicrobial resistance in the human microbiome.
Dr. Yaffe holds a PhD in Computer Science from the Weizmann Institute of Science, where he focused on epigenetics and chromatin folding. He earned his MSc in Computer Science with a specialization in the 3D structure of protein channels, and his BSc in Mathematics and Computer Science from the Hebrew University of Jerusalem. -
Alex Nathaniel Zimmet
Clinical Assistant Professor, Medicine - Infectious Diseases
BioDr. Zimmet is a board-certified Infectious Disease specialist with a focus on caring for immunocompromised patients, including those who have undergone solid organ or bone marrow transplantation as well as patients with cancer. He is an associate medical director of the antimicrobial stewardship program at Stanford Health Care, where he leads stewardship efforts in immunocompromised patients. He also has a great interest in clinical reasoning and the education and mentorship of trainees.
-
Andrew Zolopa
Professor of Medicine (Infectious Diseases) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsDr. Zolopas research applies a variety of clinical epidemiologic methods in an effort to optimize antiretroviral therapy and understand the impact of drug resistance on response to ARV. Areas of focus include the clinical application of resistance testing in optimizing antiretroviral therapy, clinical cohorts, trials of antiretroviral therapies and population-based epidemiologic evaluation of HIV resistance and efficacy of ARV therapy. More recently studies focused on premature aging in HIV.
